Yu Bing
Central Clinical School, Faculty of Medicine and Health, University of Sydney/Department of Medical Genomics, Royal Prince Alfred Hospital, Sydney NSW 2050, Australia.
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Nov;22(11):1143-1148. doi: 10.7499/j.issn.1008-8830.2006032.
Pharmacogenomics is an emerging tool to improve the efficacy and safety of drug treatment through the DNA analysis in the genes related to drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics). Clinicians need to integrate the genomic data in their benefit-risk assessment and then provide the right drug to the right patient at the right time. This tool can help to prevent an ineffective treatment, select right dose and reduce adverse drug reactions that are common in the current practice under the trial-observation-adjustment model. Pharmacogenomics may have extensive impacts on unique paediatric patients to enhance a better relationship between medical professionals and affected children or their guardians and to improve the drug compliance. Clinicians should embrace the advancements in pharmacogenomics and actively participate in clinical research to identify the ancestor-related alleles and develop the population-specific gene panel. It will allow patients to enjoy more achievements in pharmacogenomics by implementing it in first line clinical practice.
药物基因组学是一种新兴工具,通过对与药物浓度(药代动力学)和药物作用(药效动力学)相关基因的DNA分析来提高药物治疗的有效性和安全性。临床医生需要在其获益风险评估中整合基因组数据,然后在正确的时间为正确的患者提供正确的药物。该工具有助于防止治疗无效、选择合适的剂量并减少在当前试验-观察-调整模式下常见的药物不良反应。药物基因组学可能会对特殊的儿科患者产生广泛影响,以加强医疗专业人员与受影响儿童或其监护人之间的良好关系,并提高药物依从性。临床医生应接受药物基因组学的进展,并积极参与临床研究,以识别与祖先相关的等位基因并开发针对特定人群的基因检测板。通过在一线临床实践中实施药物基因组学,将使患者在其中获得更多成果。